Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 17, 2015

View Archived Issues

Clinical evidence of the utility of a new drug delivery system for the treatment of autism

New device shows potential for monitoring patients under OAT

Uncovering a drug-targetable proinflammatory pathway associated with acute respiratory syndrome

Dipraglurant demonstrates efficacy in multiple preclinical models

Azapeptide analogue exerts cardioprotective effects

Genmab enters into license agreement with Novo Nordisk for DuoBody technology

Neurocrine completes enrollment in phase III trial of NBI-98854

Bristol-Myers Squibb patents factor XIa and KLKB1 inhibitors

Allergan describes formyl peptide modulators

Roche to acquire GeneWEAVE BioSciences

Bayer Schering Pharma patent details antimitotic agents

Neuropore Therapies divulges ASYN aggregation inhibitors

AbbVie reports TrK-A inhibitors

Funding supports Biogazelle's work on long non-coding RNAs in cancer

Proteon initiates second phase III study of vonapanitase

FDA approves IND for Saniona's NS-2359 in the treatment of cocaine addiction

AXIM conducting clinical trials of MedChew RX chewing gum in Europe

Merck & Co. discloses novel series of BACE1 inhibitors for AD

First patients randomized in phase IIa trial of SER-150 in diabetic nephropathy

CDC exercises contract options for Emergent's VIGIV program

Phase II BIRCH study of atezolizumab meets primary endpoint

Phase I/II study of INV-103 in systemic lupus erythematosus complete

Onconova Therapeutics submits IND for new phase III study of intravenous rigosertib

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...